{"id":98499,"date":"2017-02-10T11:37:33","date_gmt":"2017-02-10T11:37:33","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=98499"},"modified":"2017-02-10T11:37:33","modified_gmt":"2017-02-10T11:37:33","slug":"global-renal-cell-carcinoma-market-pipeline-analysis-share-trends-and-forecast-by-2021","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/global-renal-cell-carcinoma-market-pipeline-analysis-share-trends-and-forecast-by-2021_98499.html","title":{"rendered":"Global Renal Cell Carcinoma Market Pipeline Analysis, Share, Trends and Forecast by 2021"},"content":{"rendered":"
\"\"<\/a><\/p>\n
\n
“Orbis Research”<\/div>\n<\/div>\n<\/div>\n
OrbisResearch.com has published new research report on “Renal Cell Carcinoma-Global Drugs Market Forecast and Pipeline Analysis to 2021” to its database.<\/div>\n

Renal cell carcinoma is the most common type of kidney cancer in adults. It accounts for approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney. The global renal cell carcinoma drugs market is anticipated to cross US$ 4.3 Billion mark by 2021. There are many factors, like smoking, hypertension, unhealthy eating habits and family history, which increase the risk of occurrence of renal cell carcinoma. The major driving factors for the renal cell carcinoma drugs market are increasing risk of lifestyle induced diseases, growing prevalence of renal cell carcinoma, increasing geriatric population base and quick diagnosis with modern imaging techniques.<\/p>\n

Browse the report<\/strong>: http:\/\/www.orbisresearch.com\/reports\/index\/renal-cell-carcinoma-global-drugs-market-forecast-and-pipeline-analysis-to-2021<\/a><\/p>\n

The major drugs used for the treatment of renal cell carcinoma include Sutent, Nexavar, Votrient, Avastin and Inyta amongst others. Sutent accounts for largest share of the global renal cell carcinoma drugs market in 2015, while, Votrient is projected to witness the strongest growth during the forecasting period. The most recent drugs approved for the treatment of renal cell carcinoma is Bristol-Myers Squibb’s Opdivo. Moreover, there are many pipeline drugs in various phases of clinical trials, which will fuel the growth of renal cell carcinoma drugs market.<\/p>\n

iGATE RESEARCH report entitled “Renal Cell Carcinoma – Global Drugs Market Forecast and Pipeline Analysis to 2021” provides a comprehensive analysis of the fast-evolving high growth renal cell carcinoma therapeutics market.<\/p>\n

Request a sample of the report: <\/strong>http:\/\/www.orbisresearch.com\/contacts\/request-sample\/175235 <\/a><\/p>\n

This 148 Page report with 58 Figures and 4 Tables has been analyzed from 7 viewpoints: <\/strong>
1. Renal Cell Carcinoma (RCC) – Disease Overview
2. Renal Cell Carcinoma (RCC) – Epidemiology
3. Global Renal Cell Carcinoma – Diagnosed Incident Cases to 2023 (8 Countries Covered)
4. Global Renal Cell Carcinoma – Five-Year Diagnosed Prevalent Cases to 2023 (8 Countries Covered)
5. Global Renal Cell Carcinoma – Major Branded Drugs Product Profiles and Sales Analysis to 2021 (11 Brands Covered)
6. Global Renal Cell Carcinoma Drugs – Pipeline Analysis (18 Drugs Covered)
7. Global Renal Cell Carcinoma Drugs – Market Drivers and Restraints<\/p>\n

Global Renal Cell Carcinoma – Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases to 2023 (8 Countries Covered)<\/strong>
1. United States
2. Italy
3. Germany
4. France
5. United Kingdom
6. Spain
7. Japan
8. China<\/p>\n

Global Renal Cell Carcinoma – Major Branded Drugs Product Profiles and Sales Analysis to 2021 (11 Brands Covered)<\/strong>
1. Sutent (Sunitinib)
2. Nexavar (Sorafenib)
3. Votrient (Pazopanib)
4. Avastin (Bevacizumab)
5. Afinitor (Everolimus)
6. Inlyta (Axitinib)
7. Torisel (Temsirolimus)
8. Proleukin (Aldesleukin)
9. Opdivo (Nivolumab) – Product Profile
10. Tarceva (Erlotinib) – Product Profile
11. Interferon-alfa – Product Profile<\/p>\n

Buy the report@<\/strong>http:\/\/www.orbisresearch.com\/contact\/purchase\/175235<\/a><\/p>\n

Global Renal Cell Carcinoma Drugs – Pipeline Analysis (17 Companies Drugs Covered)<\/strong>
1. Merck & Co., Inc.
2. Exelixis Inc
3. Argus Therapeutics, Inc.
4. Bristol-Myers Squibb
5. Genentech\/Roche
6. Immatics Biotechnologies
7. AVEO Oncology
8. Eisai
9. Acceleron
10. Rexahn Pharmaceuticals
11. Bionomics
12. Cerulean Pharma Inc
13. Celldex Therapeutics
14. TVAX Biomedical
15. TRACON Pharmaceuticals
16. Eli Lilly
17. AstraZeneca<\/p>\n

Data Sources<\/strong>
iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.<\/p>\n

Research Methodologies<\/strong>
Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.
Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.<\/p>\n

About Us:<\/strong><\/p>\n

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Orbis Research
Contact Person:<\/strong> Hector Costello, Senior Manager – Client Engagements
Email:<\/strong> sales@orbisresearch.com
Phone:<\/strong> +1 (214) 884-6817, +9164101019
Address:<\/strong>4144N Central Expressway, Suite 600
City:<\/strong> Dallas
State:<\/strong> Texas
Country:<\/strong> United States
Website:<\/strong> http:\/\/www.orbisresearch.com\/reports\/index\/renal-cell-carcinoma-global-drugs-market-forecast-and-pipeline-analysis-to-2021<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

“Orbis Research” OrbisResearch.com has published new research report on “Renal Cell Carcinoma-Global Drugs Market Forecast and Pipeline Analysis to 2021” to its database. Renal cell carcinoma is the most common type of kidney cancer in adults. It accounts for approximately … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-98499","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/98499","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=98499"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/98499\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=98499"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=98499"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=98499"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}